´ëÇÑÆó¾ÏÇÐȸ (ÇÏÀ̺긮µå)2022 KALC International Conference-1ÀÏÂ÷ : 2022-11-10±³À°ÀÏÀÚ : 2022-11-10
±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ¿ùµå Å©¸®½ºÅ»·ë(ÇÏÀ̺긮µå Çмú´ëȸ)
±³À°ÁÖÁ¦ :
(ÇÏÀ̺긮µå)2022 KALC International Conference-1ÀÏÂ÷ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ±èÀÎÁ¤
¿¬¶ôó : 02-741-8540
À̸ÞÀÏ :
kalc@lungca.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, º´¸®°ú, ÇÙÀÇÇаú
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 110,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 07:50~08:40 Overcoming Resistance after 3rd Generation TKI Treatment in EGFR Mutant Non-Small Cell Lung Cancer Suresh S. Ramalingam(Emory Univ., USA)
ÈÞ½Ä 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 08:40~08:50 ÈÞ½Ä ()
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 08:50~09:10 Extent of Lymph Node Dissection during Sublobar Resection Yoohwa Hwang(Seoul National Univ)
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 09:10~09:30 Sublobar Resection in Compromized Patients Jeong Su Cho(Sungkyunkwan Univ.)
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 09:30~09:50 Additional Management (for Incomplete or Local Recurrence) after Sublobar Resection Seong Yong Park(Sungkyunkwan Univ.)
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 09:50~10:10 Japan Clinical Oncology Group Studies about Sublobar Resection Hisashi Saji(St. Marianna Univ., Japan)
ÈÞ½Ä 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 10:10~10:30 ÈÞ½Ä ()
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 10:30~11:00 Antibody-Drug Conjugates: A Promising Novel Therapeutic Approach in Lung Cancer David Planchard(Gustave Roussy, France)
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 11:00~11:20 EGFR-TK Degradation by PROTACs Sumi Lee(J2HBiotech)
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 11:20~11:50 LAG 3 Immunotherapy in Lung Cancer Scott Nicholas Gettinger(Yale Univ. Medical Center, USA)
ÈÞ½Ä 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 11:50~12:00 ÈÞ½Ä ()
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 12:00~12:40 Spotlighting the New 3rd generation EGFR TKI, Lazertinib: Updated Clinical Study Results & Real World Outcomes Sun Min Lim(Yonsei Univ)
ÈÞ½Ä 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 12:40~13:00 ÈÞ½Ä ()
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 13:00~13:30 Expanding the Benefits of Immunotherapy for Cancer: Combine and Conquer Dan G. Duda(Harvard Medical School, USA)
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 13:30~14:05 Atezolizumab-Grab: Beyond the PD-L1 Blockade in Cancers Keehoon Jung(Seoul National Univ)
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 14:05~14:40 Combination of Two Distinct Subsets of Peripheral Blood CD8+ T Cells from Patients with Non-Small Cell Lung Cancer Predicts Response Outcome to Immune Checkpoint Blockade Therapy Jae Ho Cho(Chonnam National Univ.)
ÈÞ½Ä 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 14:40~15:00 ÈÞ½Ä ()
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 15:00~15:30 Chest Imaging of Treatment-Related Pneumonitis Hyae Young Kim(National Cancer Center)
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 15:30~16:00 How to Deal with Treatment-Related Pneumonitis Sun Min Lim(Yonsei Univ.)
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 16:00~16:40 Optimal Management of Radiation and Drug Related Pneumonitis in Unresectable Stage III Non-Small Cell Lung Cancer Patients William N. William(UT MD Anderson Cancer Center, USA)
ÈÞ½Ä 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 16:40~16:50 ÈÞ½Ä ()
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 16:50~17:40 Pembrolizumab Combination Strategies in Lung Cancer: Present and Future Bin Zhao(MSD Global Clinical Research)